Recordati SpA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0003828271
EUR
48.20
0.12 (0.25%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Recordati SpA stock-summary
stock-summary
Recordati SpA
Pharmaceuticals & Biotechnology
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Company Coordinates stock-summary
Company Details
Via M. Civitali, 1 , MILANO None : 20148
stock-summary
Tel: 39 02 48787139 02 48787393
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Alfredo Altavilla
Non-Executive Chairman of the Board
Dr. Andrea Recordati
Chief Executive Officer, Executive Director
Guido Guidi
Vice Chairman of the Board
Adv. Michaela Castelli
Lead Independent Non-Executive Director
Francesco Balestrieri
Director
Piergiorgio Peluso
Independent Director
Ms. Silvia Elisabetta Candini
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
644 Million
(Quarterly Results - Jun 2025)
Net Profit:
91 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 9,883 Million ()

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

22.92%

stock-summary
Debt Equity

0.86

stock-summary
Return on Equity

22.64%

stock-summary
Price to Book

5.13